v.51 (2001).
Minami, K., M. Okuno, K. Miyawaki, et al. “Lineage Tracing and Characterization of Insulin-Secreting Cells Generated From Adult Pancreatic Acinar Cells.” Proceedings of the National Academy of Sciences of the USA, v.102/42 (2005).
Narayan, K. M., J. P. Boyle, T. J. Thompson, et al. “Lifetime Risk for Diabetes Mellitus in the United States.” JAMA, v.290 (2003).
Oshima, Y., A. Suzuki, K. Kawashimo, et al. “Isolation of Mouse Pancreatic Ductal Progenitor Cells Expressing CD133 and c-Met by Flow Cytometric Cell Sorting.” Gastroenterology, v.132 (2007).
Raimya, V. K., M. Maraist, K. E. Arfors, et al. “Reversal of Insulin-Dependent Diabetes Using Islets Generated in Vitro From Pancreatic Stem Cells.” Nature Medicine, v.6/3 (2000).
Ratajczak, M. Z., E. Zuba-Surma, M. Kucia, et al. “Pluripotent and Multipotent Stem Cells in Adult Tissues.” Advances in Medical Sciences, v.57/1 (2012).
Rossant, J. “Stem Cells from the Mammalian Blastocyst.” Stem Cells, v.19/6 (2001).
Ryan, E. A., J. R. Lakey, B. W. Paty, et al. “Successful Islet Transplantation: Continued Insulin Reserve Provides Long-Term Glycemic Control.” Diabetes, v.51 (2002).
Ryan, E. A., J. R. Lakey, R. V. Rajotte, et al. “Clinical Outcomes and Insulin Secretion After Islet Transplantation With the Edmonton Protocol.” Diabetes, v.50 (2001).
Ryan, E. A., B. W. Paty, P. A. Senior, et al. “Five-Year Follow-Up After Clinical Islet Transplantation.” Diabetes, v.54 (2005).
Scharp, D. W., P. E. Lacy, J. V. Santiago, et al. “Insulin Independence After Islet Transplantation Into Patient.” Diabetes, v.39 (1990).
Seaberg, R. M., S. R. Smukler, T. J. Kieffer, et al. “Clonal Identification of Multipotent Precursors From Adult Mouse Pancreas That Generate Neural and Pancreatic Lineages.” Nature Biotechnology, v.22/9 (2004).
Shapiro, A. M., J. R. Lakey, E. A. Ryan, et al. “Islet Transplantation in Seven Patients With Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen.” New England Journal of Medicine, v.343 (2000).
Soria, B., F. J. Bedoya, and F. Martin. “Gastrointestinal Stem Cells: I. Pancreatic Stem Cells.” American Journal of Physiology, Gastrointestinal and Liver Physiology, v./2 (2005).
Tan, S.-L., P. Doyle, S. Campbell, et al. “Obstetric Outcome of in Vitro Fertilization Pregnancies Compared With Normally Conceived Pregnancies.” American Journal of Obstetrics and Gynecology, v.167/3 (1992).
Tsang, W. G., T. Zheng, Y. Wang, et al. “Generation of Functional Islet-Like Clusters After Monolayer Culture and Intracapsular Aggregation of Adult Human Pancreatic Islet Tissue.” Transplantation, v.83 (2007).
UK Prospective Diabetes Study Group. “Overview of 6 Years’ Therapy of Type II Diabetes: A Progressive Disease” (UKPDS 16). Diabetes, v.44 (1995).
Volarevic, V., B. Ljujic, P. Stojkovic, et al. “Human Stem Cell Research and Regenerative Medicine—Present and Future.” British Medical Bulletin, v.99/1 (2011).
Xu, X., J. D’Hoker, G. Stangé, et al. “Beta Cells Can Be Generated From Endogenous Progenitors in Injured Adult Mouse Pancreas.” Cell, v.132 (2008).
Zimmet, P., K. G. Alberti, and J. Shaw. “Global and Societal Implications of the Diabetes Epidemic.” Nature, v.414 (2001).
Zulewski, H. “Stem Cells With Potential to Generate Insulin-Producing Cells in Man.” Swiss Medical Weekly, v.136/41–42 (2006).
Zulewski, H., E. J. Abraham, M. J. Gerlach, et al. “Multipotential Nestin-Positive Stem Cells Isolated From Adult Pancreatic Islets Differentiate Ex Vivo Into Pancreatic Endocrine, Exocrine, and Hepatic Phenotypes.” Diabetes, v.50 (2001).
Advanced Cell Technology
Advanced Cell Technology
25
27
Advanced Cell Technology
Advanced Cell Technology (ACT) is a biotechnology company that specializes in developing cellular therapies to treat human diseases and was one of the first companies to run an FDA-approved clinical trial based on embryonic stem cells. The corporate offices and principal laboratory for ACT are located in Marlborough, Massachusetts, where the company is headed by Ted Myles (interim president, chief financial officer, and executive vice president of Corporate Development) who began at ACT in June 2013, and Robert Lanza, MD (chief scientific officer), who began working at ACT in 1999. Lanza is also an adjunct professor at the Wake Forest University School of Medicine in the Institute of Regenerative Medicine. ACT owns or licenses over 150 patents, including a broad patent for producing retinal pigment epithelial (RPE) cells for degenerative retinal disease.
ACT began working in animal cloning in the mid-1990s, but shifted its research focus to human cells in 1998, shortly after the first isolation of human embryonic stem cells (hESC). Michael West became ACT’s chief executive in 1998, and in 1999 bought the company. West recruited Robert Lanza to ACT, and the company focused on therapeutic cloning, a method of developing stem cell lines from a patient’s own cell, thus avoiding the potential for rejection of cells created from unrelated embryos.
In 2001, ACT scientists published a paper in the online journal Biomed describing a method for cloning a human embryo. Thereafter, West appeared on the television program Meet the Press to discuss the paper, bringing publicity to the company. However, according to Corie Lok in a 2012 article in Nature, that announcement may have backfired because the ACT scientists’ accomplishments were not considered significant by the scientific community (in part because the embryo they produced stopped dividing far short of what would be required to derive stem cells), but did trigger a public and political reaction that confused hESC research and cloning.
In order to raise funds, ACT merged in 2005 with the Utah-based company Two Moons Kachina and became a publicly traded firm. The company expanded and, in August 2006, Lanza and colleagues announced in Nature that they had developed a method to derive stem cells from a single cell removed from an embryo. This method could potentially allow stem cells to be produced without harming the embryo, but the embryos used in the reported study were destroyed in the process. According to Lok, this distinction was not made clear in the study or in press releases regarding the study and many news outlets reported that the company had developed a method to derive stem cells without destroying an embryo. If this claim had been true, ACT’s process would avoid some of the ethical concerns surrounding stem cell research. When it became clear that ACT did not have a method for deriving stem cells without destroying the embryo, it hurt the company’s reputation and made it difficult to attract investors.
ACT’s current research and development process has four main focuses, two of which are based on hESC. The first hESC-based therapy, RPE therapy, is intended to treat degenerative retinal disease. RPE therapy is currently undergoing Phase I/II clinical trials for adults (over 18 years) in the United States and the European Union as a treatment for Stargardt’s Macular Dystrophy and atrophic (dry) AMD (age-related macular degeneration). This phase of testing is primarily to determine the safety and toleration of the treatment, which involves the transplantation
